Preclinical studies with other GLP-1 receptor agonists have demonstrated limited brain uptake, suggesting minimal blood-brain barrier penetration, though tirzepatide-specific human data are limited
Like all aspects of being human, there is diversity in our GLP-1 system, depending on our metabolic health profile (Huber et al, 2024)
Growth hormone is a 191 amino acid peptide that has been changed
The global GLP-1 receptor agonist market is rapidly expanding due to the rising prevalence of type 2 diabetes and obesity, which have become major public health concerns
Insurance is not required to get started
Potential risks and side effects of semaglutide: Stomach paralysis or gastroparesis Bowel obstruction Deep vein thrombosis (DVT) Malnutrition-related disorders The risk for these side effects may increase with higher doses of semaglutide and prolonged use of the medication